 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
0 News |  |
- SR604 / Equilibra Biosci
Safety and efficacy of anti-human activated protein C antibody SR604 for prophylaxis of congenital factor deficiencies (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_997;
SR604 exhibited prophylactic and therapeutic efficacy in the tail bleeding and knee injury models of hemophilia A and B mice expressing human APC (humanized hemophilia mice). SR604 did not interfere with the cyto-protection and endothelial barrier function of APC nor have obvious toxicity effects in humanized hemophilia mice.
- | human immunoglobulin (pH4) for intravenous injection / Peking Union Medical College, Gammaraas (human immunoglobulin (pH4) intravenous) / Shanghai RAAS
Journal: Intravenous immunoglobulin protects the integrity of the intestinal epithelial barrier and inhibits ferroptosis induced by radiation exposure by activating the mTOR pathway. (Pubmed Central) - Apr 10, 2024
Rapamycin, which is a potent inhibitor of the mTOR protein, significantly abolished the protective effect of IVIg against radiation-induced damage to intestinal epithelial tight junctions. Overall, IVIg can prevent RE-induced damage to the intestinal epithelial barrier and inhibit ferroptosis by activating the mTOR pathway; this study provides a new treatment strategy for patients with RE caused by radiotherapy or accidental nuclear exposure.
- | HAPC1573 / Bayer, Shanghai RAAS
Journal: Safety and efficacy of anti-human activated protein C antibody SR604 for prophylaxis of congenital factor deficiencies. (Pubmed Central) - Jun 9, 2023
We engineered a humanized chimeric antibody, SR604, based on a previously published murine antibody, HAPC1573, that selectively blocks the anticoagulant activity of human activated protein C (APC)...Pharmacokinetic study showed a high bioavailability (106%) of subcutaneous SR604 injection in cynomolgus monkeys. These results demonstrate that SR604 is expected to be a safe and effective therapeutic and/or prophylactic agent with a prolonged half-life for patients with congenital factor deficiencies including hemophilia A and B.
- | human immunoglobulin (pH4) for intravenous injection / Peking Union Medical College, Gammaraas (human immunoglobulin (pH4) intravenous) / Shanghai RAAS
Journal: Sexual dimorphism in gut microbiota dictates therapeutic efficacy of intravenous immunoglobulin on radiotherapy complications. (Pubmed Central) - Apr 4, 2023
IVIg battles against radiation injuries in a sex-specific, gut microbiome-dependent way through Lachnospiraceae/hypoxanthine/PLD1 axis. Our findings provide a sex-precise therapeutic avenue to improve the prognosis of cancer patients with radiotherapy in pre-clinical settings.
- | HAPC1573 / Bayer, Shanghai RAAS
Preclinical, Journal: Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C. (Pubmed Central) - Jun 11, 2022
We further documented that HAPC1573 inhibited the APC anticoagulant activity to improve the clotting time of human plasma deficient of FVIII, FIX, FXI, FVII, VWF, FV, or FX. These results demonstrate that selectively blocking the anticoagulant activity of human APC may be an effective therapeutic and/or prophylactic approach for bleeding disorders lacking FVIII, FIX, or other clotting factors.
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Journal, Cytokine storm: Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination. (Pubmed Central) - Feb 5, 2022
Most patients (76.92%) with cytokine storm who received Gammaraas®/Actemra®, survived although they were in the severe and critical levels (87.17%). Overall, based on the treatment duration and survival rate, the most effective therapy was a combination of oseltamivir + favipiravir + hydroxychloroquine + antibiotics + vitamins/minerals.